Uveal melanoma secondary prevention

Uveal melanoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Uveal melanoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Uveal melanoma secondary prevention On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Uveal melanoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Uveal melanoma secondary prevention
CDC on Uveal melanoma secondary prevention
Uveal melanoma secondary prevention in the news
Blogs on Uveal melanoma secondary prevention
to Hospitals Treating Uveal melanoma
Risk calculators and risk factors for Uveal melanoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]

Overview

Secondary prevention strategies following uveal melanoma include dilated fundus examination, liver function tests, abdominal MRI and abdominal ultrasound.

Secondary Prevention

• Currently, there is no consensus regarding type or frequency of scans following diagnosis and treatment of the primary eye tumor. Approximately half of the patients with uveal melanoma will develop metastases within 15 years of initial diagnosis.
• Approximately 2% patients would show an evidence of metastasis at the time of initial uveal melanoma diagnosis. Of the 50% of patients who develop metastatic disease, more than 90% of patients will develop liver metastases. As such, the majority of surveillance techniques are focused on the liver.
• The surveillance techniques include regular dilated fundus examination, abdominal magnetic resonance imaging (MRI), abdominal ultrasound and liver function tests. These surveillance tests are performed every 6-12 months and can continue for many years.